Santhera Releases 2024 AGM Agenda

Pratteln, Switzerland, May 28, 2024 - Santhera Pharmaceuticals (SIX: SANN) has officially announced the details for its upcoming Annual General Meeting (AGM). The AGM is scheduled for June 18, 2024, at 10:00 CEST, and will take place at Haus der Wirtschaft, located at Hardstrasse 1, 4133 Pratteln, Switzerland.

Registered shareholders will receive the AGM invitation, which includes the agenda items and explanations, via mail. The invitation is also accessible on Santhera's website.

The AGM Agenda includes the following key points:

1. Approval of the Annual Report, Annual Financial Statements, and Consolidated Financial Statements for 2023.
2. Appropriation of the Annual Result and Offset of Deficit.
3. Consultative Vote on the Compensation Report for 2023.
4. Discharge of the Members of the Board of Directors and Executive Management from Liability for the Financial Year 2023.
5. Amendments to the Articles of Incorporation.
6. Re-election of the Members of the Board of Directors and the Chairman of the Board.
7. Re-election of the Members of the Compensation Committee.
8. Approval of the Compensation for the Members of the Board of Directors.
9. Approval of the Compensation for the Members of the Executive Management.
10. Re-election of the Statutory Auditors.
11. Re-election of the Independent Proxy.

Santhera Pharmaceuticals is a Swiss specialty pharmaceutical company dedicated to developing and commercializing innovative treatments for rare neuromuscular and pulmonary diseases that have significant unmet medical needs. The company holds an exclusive global license from ReveraGen for AGAMREE® (vamorolone), a dissociative steroid with a unique mode of action. AGAMREE® has been studied in a pivotal trial for Duchenne muscular dystrophy (DMD) and is intended as an alternative to traditional corticosteroids.

AGAMREE® has received approval for DMD treatment from the U.S. Food and Drug Administration (FDA), the European Medicines Agency (EMA), and the UK's Medicines and Healthcare products Regulatory Agency (MHRA). Santhera has also licensed the rights to AGAMREE® for North America to Catalyst Pharmaceuticals, Inc. and for China to Sperogenix Therapeutics.

Santhera Pharmaceuticals emphasizes that this communication does not serve as an offer or invitation to purchase or subscribe to any securities of the company. The publication may include forward-looking statements about the company and its business. These statements are subject to risks, uncertainties, and other factors that could lead to actual results that differ significantly from those expressed or implied. Readers are advised not to rely heavily on these statements, especially in connection with any contractual or investment decisions. The company is not obliged to update any forward-looking statements.

How to obtain the latest research advancements in the field of biopharmaceuticals?

In the Synapse database, you can keep abreast of the latest research and development advances in drugs, targets, indications, organizations, etc., anywhere and anytime, on a daily or weekly basis. Click on the image below to embark on a brand new journey of drug discovery!